Emmaus Life Sciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, disclosing a net loss of $6,737 thousand for the nine months ended September 30, 2026, alongside a total stockholders' deficit of $68,652 thousand.
Key Highlights
- Nine-month net loss: The company reported a net loss of $6,737 thousand for the nine months ended September 30, 2026, compared to a net loss of $5,541 thousand for the same period in 2025.
- Third-quarter revenue decline: Net revenues for the three months ended September 30, 2026 were $1,892 thousand, down from $3,378 thousand in the same quarter of 2025.
- Nine-month revenue increase: Net revenues for the nine months ended September 30, 2026 were $10,192 thousand, up from $8,601 thousand for the nine months ended September 30, 2025.
- Conversion feature derivative liability: A new conversion feature derivative on notes payable of $3,247 thousand appeared on the balance sheet as of September 30, 2026, with a corresponding fair value change loss of $3,247 thousand recorded over the nine-month period.
- Total assets and liabilities: Total assets were $17,735 thousand and total liabilities were $86,387 thousand as of September 30, 2026, resulting in a total stockholders' deficit of $68,652 thousand.
- Shares outstanding: The company had 70,188,263 shares of common stock outstanding as of November 11, 2026.
- Accumulated deficit: The accumulated deficit reached $276,804 thousand as of September 30, 2026, compared to $270,067 thousand at December 31, 2025.
Emmaus Life Sciences Financial Results for the Nine Months Ended September 30, 2026
According to the filing, Emmaus Life Sciences, Inc. reported net revenues of $10,192 thousand for the nine months ended September 30, 2026, an increase from $8,601 thousand in the comparable prior-year period. For the third quarter alone, revenues of $1,892 thousand represented a decline from $3,378 thousand in the three months ended September 30, 2025. The company reported gross profit of $9,311 thousand for the nine-month period, compared to $7,979 thousand in 2025, while gross profit for the third quarter was $1,523 thousand versus $3,131 thousand a year earlier.
The filing disclosed a loss from operations of $369 thousand for the three months ended September 30, 2026, and income from operations of $2,599 thousand for the nine-month period. However, total other expense of $9,329 thousand for the nine months ended September 30, 2026 drove the pre-tax loss to $6,730 thousand. A significant component was a $3,247 thousand loss from the change in fair value of a conversion feature derivative on notes payable, which the filing states first appeared on the balance sheet in the current period. Interest expense for the nine months was $5,587 thousand, up from $4,865 thousand in the prior year.
As of September 30, 2026, the company reported cash and cash equivalents of $971 thousand, down from $2,127 thousand at December 31, 2025. Total current liabilities were $72,886 thousand against total current assets of $4,681 thousand. The filing identifies the company as a non-accelerated filer and smaller reporting company. No securities are registered under Section 12(b) of the Act, according to the cover page. The filing notes the registrant is incorporated in Delaware and headquartered in Torrance, California.
What Was Disclosed
Emmaus Life Sciences filed its quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $6,737 thousand, a total stockholders' deficit of $68,652 thousand, and the emergence of a $3,247 thousand conversion feature derivative liability on notes payable.




Please wait processing your request...